Results 191 to 199 of about 7,693 (199)
Some of the next articles are maybe not open access.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Lancet Oncology, The, 2010
Saul H Rosenberg
exaly  

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

Investigational New Drugs, 2014
James M Cleary   +2 more
exaly  

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology, 2015
Whitney P Kirschbrown
exaly  

Navitoclax/Venetoclax

Reactions Weekly
openaire   +1 more source

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma

Proceedings of the National Academy of Sciences of the United States of America, 2016
Kelli M Wilson   +2 more
exaly  

Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis

Medicom Conference Report EHA 2024
openaire   +1 more source

­Navitoclax Reduces Biomarkers of Senescence, SASP, and Neurodegeneration in Aged Nonhuman Primates

Edward Greenberg   +28 more
openaire   +1 more source

Navitoclax inhibits senescence in human alveolar type 2 cells from COPD patients

Airway pharmacology and treatment
Yiling Guo   +5 more
openaire   +1 more source

Navitoclax inhibits senescence markers in precision cut lung slices from COPD patients

Airway pharmacology and treatment
Peter Fenwick   +5 more
openaire   +1 more source
apoptosis
senescence
senolytics
bcl-xl
cellular senescence
bcl-2
cell death
medicine
oncology
previous   18  19  20  

Home - About - Disclaimer - Privacy